Hemophilia & Bleeding Disorders
Advanced clotting factors and innovative therapies for comprehensive bleeding disorder management including 2025 FDA-approved novel biologics
2025 Treatment Breakthroughs
Fitusiran (Qfitlia)
FDA-approved March 2025 - siRNA therapy for Hemophilia A/B. Administered subcutaneously once every 2 months.
Marstacimab (Hympavzi)
2025 approval - 35% reduction in bleeding vs prophylaxis. TFPI inhibitor for adults and adolescents.
Extended Half-Life Factors
EHL factor concentrates with molecular modifications for reduced treatment frequency and improved adherence.
Loading medicines...
Specialized Hemophilia Support Services
24/7 Emergency Supply
Immediate factor delivery for bleeding emergencies
Home Infusion Support
Training and assistance for self-administration
Comprehensive Care
Connect with hemophilia treatment centers
Need Hemophilia Medication Support?
Our specialized team provides comprehensive support for bleeding disorder patients
Medical Disclaimer: Hemophilia and bleeding disorder medications require careful dosing and monitoring by hematologists. Factor replacement should be calculated based on individual patient weight and severity. Always maintain emergency factor supplies and contact information for hemophilia treatment centers.